Recursion Pharmaceuticals, Inc. Class A Common Stock

RXRXNASDAQ • USD
ThemeBiotech - Drug Development›Clinical-Stage Platforms
3.32 USD
↘ 0.48 (12.76%)AT CLOSE (11:59 AM EDT)
3.29
↘ 0.02 (0.63%)
POST MARKET (AS OF 08:00 PM EDT)
Post Market
AS OF 08:00 PM EDT
3.29
↘ 0.02 (0.63%)
🔴Market: CLOSED
Open?$3.63
High?$3.70
Low?$3.21
Prev. Close?$3.80
Volume?26.9M
Avg. Volume?17.7M
VWAP?$3.38
Rel. Volume?1.52x
Bid / Ask
Bid?$3.28 × 100
Ask?$3.31 × 1.5K
Spread?$0.03
Midpoint?$3.30
Valuation & Ratios
Market Cap?1.8B
Shares Out?524.7M
Float?409.8M
Float %?78.5%
P/E Ratio?N/A
P/B Ratio?1.72
EPS?-$1.05
Dividend?0.00%
Ex-Dividend?N/A

Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) is currently trading at $3.32. Technical and fundamental signals converge bearish — technicals rate "Sell" while fundamentals read "Sell". Key drivers include a concerning Altman Z-Score in the distress zone, negative Return on Equity and a bearish Death Cross on the long-term moving averages. RXRX is fairly valued relative to its sector peers based on current multiples.

Technical & fundamental data as of Jun 5, 2026.

News
Profile
Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery. Geographically, the company operates in United States, United Kingdom, and Others. It derives maximum revenue from United States.
Themes
Biotech - Drug Development›Clinical-Stage PlatformsAI & Machine Learning›AI-Powered Analytics & Decision Systems
Employees
600
Market Cap
1.8B
Industry
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Website
www.recursion.com
Listed
2021-04-16
Address
41S RIO GRANDE STREET
SALT LAKE CITY, UT 84101
Phone: (385) 269-0203
Technical OutlookSell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-1/3)
Medium-Term (Wave)?▼ Bearish(-1/3)
Short-Term (Ripple)?▼ Bearish(-3/3)
MA Alignment?Mixed
Full Technical Analysis →
Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?
23
Z-Score?
3
Momentum?
77
Short Sent.?
25
Piotroski F-Score?3/9Weak
Altman Z-Score?0.19Distress
Confidence?54%Low
Full Fundamental Analysis →
Short InterestSqueeze Risk
Short % of Float?45.00%Squeeze Risk
Short Interest?184.4M
Days to Cover?13.3
Free Float409.8M
Avg Daily Volume13.9M
Settlement Date2026-05-15
Financial Health
Current Ratio?5.43Strong
Quick Ratio?5.43Strong
Cash Ratio?5.05Strong
Debt/Equity?0.02Low
ValuationFAIRLY VALUEDvs 1 peers + S&P 500
Score
67/100
P/E?
N/A▾
P/B?
Peers
100
S&P
82
1.72CHEAP▾
P/S?
Peers
100
S&P
3
26.53HIGH▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-2.2CHEAP▾
EV/Sales?
Peers
100
S&P
3
16.93HIGH▾
Returns & Efficiency
ROE?
S&P
3
-54.6%WEAK▾
ROA?
S&P
3
-41.8%WEAK▾
Cash Flow & Enterprise
FCF?$-325847000
Enterprise Value?$1.1B
Fundamentals ratios updated end of day
MarketsMoversWatchlist